IgA Nephropathy clinical trials at University of California Health

9 in progress, 4 open to eligible people

Showing trials for

  • Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

    at UCLA

  • TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done

    at UC Irvine UCSF

  • Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.

    at UC Davis UCSF

  • Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

    at UCLA UCSF

  • Zigakibart in Adults With IgA Nephropathy

    Sorry, in progress, not accepting new patients

    Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

    at UCSF

  • Atacicept in Subjects With IgA Nephropathy

    Sorry, in progress, not accepting new patients

    A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

    at UCLA

  • Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

    Sorry, not yet accepting patients

    This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney failure. The AIP diet avoids foods that may cause inflammation (like dairy, grains, and sugar) for 8 weeks, then gradually reintroduces them over 4 months. We're enrolling 30 adults aged 18-65 with IgAN and protein in their urine to try this diet for 6 months. Participants will track their urine protein daily at home, keep a food log, and have monthly lab checkups, with support from a diet expert. The main goal is to see if the diet reduces urine protein by 20% or more, which could slow disease progression and reduce the need for treatments like dialysis. This exploratory study aims to find out if diet changes can help manage IgAN.

    at UCLA

  • LNP023 in Primary IgA Nephropathy Patients

    Sorry, in progress, not accepting new patients

    The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

    at UCLA

  • Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

    Sorry, in progress, not accepting new patients

    This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy.

    at UCSD UCSF

Our lead scientists for IgA Nephropathy research studies include .

Last updated: